Depressed left ventricular (LV) ejection fraction (EF) adversely affects procedural outcome during percutaneous coronary revascularization. This study examined the acute results, effectiveness, and safety of excimer laser coronary angioplasty (ELCA) in patients with acute coronary ischemic syndromes whose LVEF was depressed (<40%) versus those with preserved LVEF. One hundred patients with acute coronary syndromes (51 with unstable angina and 49 with acute myocardial infarction) underwent ELCA. Twenty-five patients (group 1) (29 lesions; 72% thrombotic) had decreased LVEF (mean 28 +/- 6%) and 75 patients (group 2) (81 lesions; 60% thrombotic) had preserved LVEF (mean 53 +/- 8%). Group 1 had a higher incidence of 3-vessel disease, Q-wave acute myocardial infarction, cardiogenic shock, diabetes, and hypertension. High laser success (87% group 1 vs 93% group 2, p = NS) and procedural success (93% group 1 vs 98% group 2, p = NS) were achieved in both groups. Minimal luminal diameter in group 1 increased from 0.7 +/- 0.5 to 1.4 +/- 0.5 mm after the laser procedure and finally to 3.0 +/- 0.4 mm; in group 2, minimal luminal diameter increased from 0.7 +/- 0.4 to 1.3 +/- 0.5 mm after the procedure to a final of 3.0 +/- 0.5 mm. The laser energy vaporized 75% of thrombus burden from the target lesion in group 1 versus 79% in group 2 (p = NS). Thrombolysis In Myocardial Infarction flow in group 1 increased from 1.4 +/- 1.2 to 2.7 +/- 0.7 by laser and finally to 2.9 +/- 0.3, and in group 2 from 2.0 +/- 1.0 to 2.8 +/- 0.6 after the laser procedure to a final of 2.9 +/- 0.4. There were no deaths, emergency bypass surgeries, strokes, or acute vessel closures in either group. Thus, ELCA is a safe and feasible revascularization modality for patients with acute coronary syndromes whose LVEF is depressed. The laser energy vaporizes a large thrombus burden from the treated plaque. Angiographic intracoronary thrombus does not adversely affect device and procedural success in these select patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9149(03)00010-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SMILE for correction of myopia in patients during the incipient phase of presbyopia.
Int Ophthalmol
January 2025
Department of Ophthalmology, Peking University Third Hospital, No 49 Huayuan North Road, Haidian District, Beijing, 100191, China.
Purpose: To evaluate clinical outcomes and visual quality 12 months after small incision lenticule extraction (SMILE) for correction of myopia with or without astigmatism in patients during the incipient phase of presbyopia.
Setting: Peking University Third Hospital, Beijing, China.
Design: Retrospective observation study.
Three-Year Results of Combining Debulking Devices with Drug-coated Balloons for the Treatment of De Novo Femoropopliteal Arteriosclerosis Obliterans.
Ann Vasc Surg
January 2025
Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Electronic address:
Objectives: To compare the safety and efficacy of debulking devices, including directional atherectomy (DA) and excimer laser atherectomy (ELA), when combined with drug-coated balloons (DCB) for treating de novo femoropopliteal atherosclerotic obliterans (ASO). Additionally, to evaluate the long-term outcomes and application status of these different debulking devices.
Methods: Clinical data were collected from patients with femoropopliteal ASO who underwent combined debulking and DCBs at the Vascular Surgery Department of Xuanwu Hospital, Capital Medical University, China, between January 2018 and January 2023.
Two-Year Outcomes of Excimer Laser Ablation Combined with Drug-Coated Balloon for Treating De novo Lesions and In-Stent Restenosis in Femoropopliteal Artery of Chronic Limb-Threatening Ischemia Patients.
Ann Vasc Surg
January 2025
Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Xicheng District, Beijing, 100053. Electronic address:
Objective: To evaluate the safety and efficacy of excimer laser ablation (ELA) combined with drug-coated balloon(DCB)in the treatment of Chronic limb-threatening ischemia (CLTI) patients with de novo and in-stent restenosis (ISR) lesions in the femoropopliteal artery.
Methods: A retrospective, single-center analysis was performed on data collected between January 2017 and December 2021. The study included CLTI patients who underwent treatment with ELA combined with DCB for de novo and ISR lesions in the femoropopliteal artery.
Establishment and evaluation of rabbit model for corneal ectasia by photorefractive keratectomy.
Exp Eye Res
January 2025
Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.
View Article and Find Full Text PDFSpherical implantable collamer lens with postoperative adjunctive LASIK in the treatment of high compound hyperopic astigmatism.
BMC Ophthalmol
January 2025
Department of Ophthalmology and Visual Sciences, McGill University, 5252 Maisonneuve Blvd W, 4th floor,, Montreal, Québec, H4A 3S5, Canada.
Objective: To assess refractive and visual outcomes of a spherical Implantable Collamer Lens (ICL) followed by planned postoperative adjunctive laser-assisted in situ keratomileusis (LASIK) in the treatment of high compound hyperopic astigmatism.
Methods: In this prospective, multi-center, multi-surgeon, single-arm trial, eyes with ≥ 3.50 D hyperopia and ≥ 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!